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Performance of the 12-item WHODAS 2.0 in
prodromal Huntington disease
Ji-In Kim1, Jeffrey D Long1,2, James A Mills1, Nancy Downing3, Janet K Williams3 and Jane S Paulsen*,1,4,5
the PREDICT-HD Investigators and Coordinators of the Huntington Study Group6
The Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition (DSM-5), recommends the World Health Organization
Disability Assessment Schedule (WHODAS) 2.0 for routine clinical use. We tested the utility of the 12-item WHODAS 2.0 in
prodromal Huntington disease. Using data from 726 participants and 630 companions over a 3-year follow-up, linear mixed
models were ﬁtted to test (1) baseline and longitudinal differences by progression group; (2) participant and companion
differences within each group; and (3) sensitivity of the 12-item WHODAS in comparison to the 36-item WHODAS and the Total
Functional Capacity (TFC) score from the Uniﬁed Huntington’s Disease Rating Scale. Participants showed baseline group
differences whereas companions showed baseline and longitudinal group differences. Companions reported worse functional
decline over time than participants as the disease progresses. The 12-item WHODAS detected longitudinal change better than
the 36-item WHODAS and the TFC in the medium progression group. Results suggest the 12-item WHODAS 2.0 can detect
baseline and longitudinal differences in prodromal HD and may be useful in HD clinical trials.
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INTRODUCTION
The Diagnostic and Statistical Manual for Mental Disorders, Fifth
Edition (DSM-5), recommends the World Health Organization
(WHO) Disability Assessment Schedule (WHODAS) 2.0 as a disability
measure for routine clinical use.1 There are two versions of the
WHODAS 2.0—a full version with 36 items and a short version with
12 items. Previously, we reported that the total score of the 36-item
WHODAS 2.0 can detect longitudinal changes in daily function in
prodromal (before motor diagnosis) HD, and is better at detecting
changes in an earlier stage of HD than the Total Functional Capacity
(TFC) from the Uniﬁed Huntington’s Disease Rating Scale.2 The
current study investigates the performance of the global score of the
12-item version in a large observational study of people with
prodromal HD. The aims of the current study are (i) to test disease
progression group differences in baseline values and longitudinal
change in a separate analysis of participant and companion ratings on
the 12-item WHODAS 2.0; (ii) to compare longitudinal participant
and companion ratings on the 12-item version; and (iii) to assess the
relative sensitivity of the 12-item version in comparison with the full




A total of 726 participants and 630 companions were administered the
WHODAS 2.0 (starting in 2009) in the Neurobiological Predictors of
HD (PREDICT-HD) study3 with up to 3.11 years of follow-up. On the
basis of the HD gene-expansion test results, individuals were classiﬁed
as cases, if the cytosine-adenine-guanine (CAG) expansion ≥ 36 or
controls, if CAGo36. Cases were classiﬁed into three progression
groups based on their CAG-Age Product (CAP) capturing different
disease progression levels at baseline.4 For the low, medium, and high
CAP groups, the estimated times to motor diagnosis were412.8, 7.6–
12.8, and o7.6 years, respectively. Four groups were deﬁned in this
analysis: control, low, medium, and high. For more details, please refer
to the study by Downing et al.2
Measures
The full WHODAS includes 36 items in six domains: understanding
and communicating; getting around; self-care; getting along with
others; activities at home, work, and school; and participation in
society. Each item has ﬁve response categories (1=none; 2=mild;
3=moderate; 4= severe; 5= extreme/cannot do). The 12-item WHO-
DAS includes two items from each domain, with a total score
computed as the sum of the 12 items.1 To compare the TFC and
WHODAS, the TFC was scaled as TFC loss so that higher scores
indicate worse function for all outcomes.
Statistical analysis
Analysis 1: To examine group differences in baseline status and
longitudinal change, participant and companion ratings were analyzed
separately using linear mixed effects regression (LMER).5 Three nested
models were ﬁtted for each outcome and compared by Akaike’s
information criterion. Analysis 2: To test whether longitudinal changes
of participant and companion ratings were equal within each group,
participant and companion data were analyzed simultaneously. Sixteen
possible candidate models were ﬁtted and a model averaging method6
was applied to ﬁnd reliable slope discrepancies. Fitted curves were
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drawn using model-averaged parameters over all models. Analysis 3:
To evaluate the sensitivity of the 12-item WHODAS, comparison was
made to the TFC and the 36-item WHODAS. For each scaled
outcome, the model with baseline and longitudinal group effects
was ﬁtted and effect sizes were compared among the three outcomes.
In all analyses, models were adjusted for gender, years of education,
and age at entry.
RESULTS
Progression group differences (Aim 1)
Table 1 shows the best model for each outcome, and the estimated
baseline and longitudinal differences between controls and each
progression group. Participants showed baseline group differences
only, whereas companions showed both baseline and longitudinal
group differences. Compared with controls, participants in the
medium and high progression groups reported signiﬁcantly worse
functioning at baseline, and companions of those in the high group
reported signiﬁcantly worse functioning at baseline. In contrast, only
companions of those in the medium and high groups reported
signiﬁcantly worse functional decline over time.
Self- vs informant-rated WHODAS (Aim 2)
Figure 1 shows the ﬁtted curves for participant and companion
outcomes (analyzed simultaneously). The participant (dark blue) and
companion (light blue) curves were relatively similar in each group
from the control to the medium group, indicating similar rates of
change over time in participant and companion ratings. In contrast,
there was a divergence between the two curves in the high group,
indicating companions reported worse functional decline over time
than participants. The divergence in the high group was statistically
more reliable than the other groups.
Sensitivity of 12-item WHODAS (Aim 3)
We compared the companion 12-item WHODAS total to the TFC and
companion 36-item WHODAS total, focusing on companions because
they better detected longitudinal change than participants.2 Figure 2
shows ﬁtted curves for the scaled WHODAS and TFC. At baseline, the
12-item WHODAS (z= 3.55) had a larger difference than TFC loss
(z= 2.33) but a smaller difference than the 36-item WHODAS
(z= 3.68) in the high group. For longitudinal changes, the 12-item
WHODAS (z= 2.45) showed a larger difference than both the 36-item
Table 1 Comparison of World Health Organization Disability Assessment Schedule (WHODAS) 12-item scores between the control group and
each gene expanded group for the best models
Group differences relative to controls
Baseline differences Longitudinal differences
Measure (best model) Low est. (SE) Med est. (SE) High est. (SE) Low est. (SE) Med est. (SE) High est. (SE)
Participant 12-item Total (baseline group effect model) 0.031 (0.106) 0.224 (0.092)* 0.309 (0.087)***
Companion 12-item Total (baseline+longitudinal group
effect model)
0.187 (0.106) 0.099 (0.094) 0.301 (0.091)*** −0.057 (0.099) 0.268 (0.091)** 0.269 (0.085)**
Abbreviations: Est., estimate; SE, standard error; Med, medium. Low, Medium, and High groups indicate low, medium, and high estimated probability of motor diagnosis in 5 years, respectively.
***Po0.001, **Po0.01, *Po0.05.
Figure 1 Fitted linear mixed effects regression curves by group for participant (P) and companion (C) ratings of the 12-item World Health Organization
Disability Assessment Schedule (WHODAS) 2.0.
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WHODAS (z= 2.35) and TFC loss (z= 1.93) in the medium group.
The 12-item WHODAS (z= 2.27) showed a smaller difference than
the 36-item WHODAS (z= 2.33) and TFC loss (z= 3.76) in the
high group.
DISCUSSION
This is the ﬁrst study that we know of that has undertaken a
longitudinal analysis of the 12-item WHODAS 2.0 in a prodromal
HD sample. Both participant and companion ratings showed baseline
differences by disease progression group, whereas only companion
ratings showed longitudinal change differences by disease progression
group. To detect differences in baseline levels and longitudinal change
by progression group, the 12-item WHODAS seems to be a useful
daily function measure in prodromal HD and may be useful for future
clinical trials in HD. Companions reported a faster decline of daily
function over time than participants in the high group, suggesting
participants might experience declining self-awareness of functional
changes owing to frontal-subcortical dysfunction, which occurs in
HD.7 This result indicates proxy measures may be more reliable than
self-reported ones in later stages of prodromal HD disease progression,
and supports the DSM-5 recommendation of using proxy measures
when individuals have impaired cognitive function. Our ﬁndings with
the 12-item WHODAS were consistent with the previous longitudinal
analysis of the 36-item WHODAS.2
For individuals with prodromal HD, it has been challenging to ﬁnd
sensitive daily function measures that can detect longitudinal change.8
When we assessed the ability of the 12-item WHODAS 2.0 in
comparison with the TFC and the 36-item WHODAS 2.0, the short
version of the companion WHODAS detected more reliable functional
decline over time than the full version and TFC in the medium group.
The 12-item WHODAS was also able to detect longitudinal change in
the high group and had similar functional decline over time compared
with the 36-item WHODAS. In addition, only 10% of respondents
showed longitudinal change for the TFC unlike the 12-item WHO-
DAS, where 68% showed change over time. Therefore, the 12-item
WHODAS seems to have better sensitivity in detecting longitudinal
change in an earlier stage of prodromal HD than the TFC and the 36-
item WHODAS. The current study presents evidence that the 12-item
WHODAS 2.0 has similar psychometric properties to the full version.
This suggests the importance of selecting reliable items for a reduced
measure. In a separate analysis (unpublished), people with gene-
expansion showed longitudinal differences relative to controls in three
subscales—understanding, getting along, and life activities. Using the
largest sample of participants with prodromal HD to date, our ﬁndings
suggest the short version can be used as a general index of HD disease
progression. The 12-item version was better able to detect longitudinal
change in daily functioning in the earlier stages of prodromal HD than
the TFC and the 36-item WHODAS. The improved detection of
functional decline and the briefer administration time of the short
version suggest it might be a useful part of a clinical trial battery to test
the ability of new treatments and interventions to preserve daily
function in prodromal HD. The effect of individual items on the
performance of the 12-item WHODAS total is an area of future
research.
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